Patents by Inventor Chantal BOULANGER-ROBERT

Chantal BOULANGER-ROBERT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and kits for predicting the risk of having or developping hepatocellular carcinoma in patients suffering from cirrhosis
    Patent number: 11231422
    Abstract: Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA/filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E+) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: January 25, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique Hôpitaux de Paris (APHP), UniversitéParis Diderot—Paris 7
    Inventors: Pierre-Emmanuel Rautou, Chantal Boulanger-Robert
  • METHODS AND KITS FOR PREDICTING THE TRANSPLANTATION-FREE SURVIVAL TIME OF PATIENTS SUFFERING FROM CIRRHOSIS
    Publication number: 20200225247
    Abstract: Following a prospective clinical study that includes 242 patients, the inventors show that hepatocyte-derived MV levels predicted transplantation-free survival at 6 months in univariate analysis. In multivariate analysis, this association was shown to be independent of Child-Pugh and of MELD score. Thus the present invention thus relates to a method of predicting the transplantation-free survival time of a patient suffering from cirrhosis comprising determining the level of hepatocyte-derived microvesicles (e.g. by an ELISA assay) in a blood sample obtained from the patient.
    Type: Application
    Filed: March 20, 2018
    Publication date: July 16, 2020
    Inventors: Pierre-Emmanuel RAUTOU, Chantal BOULANGER-ROBERT
  • METHODS AND KITS FOR PREDICTING THE RISK OF HAVING OR DEVELOPPING HEPATOCELLULAR CARCINOMA IN PATIENTS SUFFERING FROM CIRRHOSIS
    Publication number: 20200033349
    Abstract: Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA/filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E+) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.
    Type: Application
    Filed: March 20, 2018
    Publication date: January 30, 2020
    Inventors: Pierre-Emmanuel RAUTOU, Chantal BOULANGER-ROBERT